Association of SARS-CoV-2 nucleocapsid viral antigen and the receptor for advanced glycation end products with development of severe disease in patients presenting to the emergency department with COVID-19

Zachary A. Matthay, Alexander T. Fields, Katherine D. Wick, Chayse Jones, H. Clifford Lane, Kimberly Herrera, Brenda Nunez‐Garcia, Efstathios D. Gennatas, Carolyn M. Hendrickson, Aaron E. Kornblith, Michael A. Matthay, Lucy Z. Kornblith, the Covid-19 Associated Coagulopathy Inflammation Thrombosis (Co-ACIT) Study GroupFrontiers in Immunology 2023 · DOI

Abstract

Elevated RAGE and SARS-CoV-2 nucleocapsid viral antigen on emergency department presentation are strongly associated with development of severe disease at 7 days. These findings are of clinical relevance for patient prognostication and triage as hospital systems continue to be overwhelmed. Further studies are warranted to determine the feasibility and utility of point-of care measurements of these biomarkers in the emergency department setting to improve patient prognostication and triage.

Introduction

Predicting the clinical trajectory of COVID-19 remains a significant challenge for emergency department (ED) clinicians. While many patients present with mild symptoms, a subset rapidly deteriorates into respiratory failure or death. Existing triage tools often rely on clinical symptoms or late-stage markers of organ damage, which may not capture the underlying biological "storm" brewing at the time of admission.

Most prior research on COVID-19 biomarkers has focused on patients already admitted to the ICU. This study addresses the gap in early prognostication: identifying high-risk patients the moment they step into the ED, allowing for earlier intervention and more efficient hospital management.

Methods

The researchers conducted a prospective cohort study as part of the Co-ACIT (COVID-19 Associated Coagulopathy Inflammation Thrombosis) Study Group. The study included 77 adult patients presenting to the Zuckerberg San Francisco General Hospital ED with symptomatic, PCR-confirmed COVID-19 between June 2020 and March 2021. Blood samples were collected immediately upon arrival.

The team measured a comprehensive suite of markers, including:

  • Viral Load: SARS-CoV-2 nucleocapsid (N) antigen.
  • Lung Injury: Soluble receptor for advanced glycation end products (RAGE), a specific marker of alveolar epithelial damage.
  • Inflammation/Endothelial Markers: A panel including IL-6, IL-10, TNFR-1, and various coagulation factors (D-dimer, PAI-1, vWF).
Table 1: Patient characteristics and clinical outcomes categorized by disease severity at 7 days.

Multivariable logistic regression was used to determine which markers independently predicted "severe disease or death" (defined by the WHO Ordinal Scale) at day 7.

Key Results

Of the cohort, 22% (17/77) developed severe disease or died within 7 days. After adjusting for multiple comparisons, RAGE, SARS-CoV-2 N-antigen, IL-6, IL-10, and TNFR-1 were significantly higher in the severe group (all p < 0.05).

In the final multivariable model, RAGE and N-antigen were the strongest independent risk factors. Specifically:

  • Log RAGE > 8.07 (~3,197 pg/ml): 87% sensitivity and 93% specificity for predicting severe disease.
  • Log N-antigen > 8.38 (~4,359 pg/ml): 82% sensitivity and 87% specificity.
Figure 1: Correlation between SARS-CoV-2 viral antigen levels and RAGE, stratified by clinical outcome at 7 days.

Both markers achieved an Area Under the Curve (AUC) of 0.85 or higher, indicating excellent diagnostic accuracy. Notably, RAGE and N-antigen remained significant predictors even after adjusting for the APACHE-III score, suggesting these biomarkers provide biological information that clinical observations miss.

Discussion and Future Directions

The study highlights the "front door" advantage of these biomarkers. Unlike markers of endothelial injury, which often manifest later, RAGE and viral antigen levels are elevated very early. RAGE acts as a direct "smoke signal" indicating that the air sacs in the lungs are already being damaged, even if the patient doesn't yet require high-flow oxygen.

While the study is limited by a modest sample size and pre-Omicron data, the findings suggest a path forward for improved triage. The authors call for the development of point-of-care (POC) assays for RAGE and N-antigen. If these markers can be measured via a rapid bedside test, they could become a standard part of the "workup" for every COVID-19 patient entering an emergency department, significantly improving resource allocation during pandemic surges.

Summary updated

Abstract

Elevated RAGE and SARS-CoV-2 nucleocapsid viral antigen on emergency department presentation are strongly associated with development of severe disease at 7 days. These findings are of clinical relevance for patient prognostication and triage as hospital systems continue to be overwhelmed. Further studies are warranted to determine the feasibility and utility of point-of care measurements of these biomarkers in the emergency department setting to improve patient prognostication and triage.
BibTeX
@inproceedings{matthay2023association,
  author = {Zachary A. Matthay and Alexander T. Fields and Katherine D. Wick and Chayse Jones and H. Clifford Lane and Kimberly Herrera and Brenda Nunez‐Garcia and Efstathios D. Gennatas and Carolyn M. Hendrickson and Aaron E. Kornblith and Michael A. Matthay and Lucy Z. Kornblith and the COVID-19 Associated Coagulopathy Inflammation Thrombosis (Co-ACIT) Study Group},
  title = {{Association of SARS-CoV-2 nucleocapsid viral antigen and the receptor for advanced glycation end products with development of severe disease in patients presenting to the emergency department with COVID-19}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1130821},
}
Figure